REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Bolt Biotherapeutics Inc. (BOLT) on Tuesday reported a loss of $15.2 million in its third quarter.
The Redwood City, California-based company said it had a loss of 40 cents per share.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 36 cents per share.
The company posted revenue of $1.1 million in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $1 million.
In the final minutes of trading on Tuesday, the company's shares hit 64 cents. A year ago, they were trading at 98 cents.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BOLT at https://www.zacks.com/ap/BOLT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.